3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Lymphoid
3
Conditions
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, B-Cell
3
Lymphoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
2
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Hodgkin Disease
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
30
Rituximab
26
Biopsy
23
Specimen Handling
20
Magnetic Resonance Spectroscopy
18
fludarabine
14
Prednisone
13
Vincristine
11
obinutuzumab
10
Lenalidomide
10
Etoposide
10
Doxorubicin
10
Bendamustine Hydrochloride
9
pembrolizumab
7
venetoclax
6
fludarabine phosphate
6
X-Rays
6
Tacrolimus
6
Nuclear Medicine Department, Hospital
6
Dexamethasone
6
Bortezomib
6
trametinib
5
ibrutinib
5
glofitamab
5
acalabrutinib
5
Mycophenolic Acid
5
Gemcitabine
5
Crizotinib
5
Busulfan
5
copanlisib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Lymphoma
×
tafasitamab
×
90 days
×
Clear all
NCT04981795
2026-04-27
realMIND
Incyte Corporation
Completed
102 enrolled
NCT07030699
2026-04-07
ECLAT
Memorial Sloan Kettering Cancer Center
Phase 2
Withdrawn
NCT07502872
2026-03-31
TPG
Brown University
Phase 2
Not yet recruiting
30 enrolled